Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 11/20 | 0.63 |
| ▸ | PYGM | P11217 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | THRA | P10827 | 1/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.53 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7118351 | 0.90 | PYGL (0.54) | PYGLPYGMMAPTALDH1A1MEN1 | |
| SCHEMBL7118343 | 0.87 | ABCG2 (0.54) | PYGLPYGMMAPTALDH1A1MEN1 | |
| SCHEMBL4950322 | 0.85 | AKR1C4 (0.69) | PYGLPYGMMAPTALDH1A1MEN1 | |
| SCHEMBL29472407 | 0.85 | AKR1C4 (0.69) | PYGLPYGMMAPTALDH1A1MEN1 | |
| SCHEMBL7116140 | 0.82 | PYGL (0.66) | PYGLPYGMMAPTALDH1A1MEN1 | |
| SCHEMBL14418381 | 0.81 | AKR1C4 (0.64) | PYGLPYGMMAPTALDH1A1MEN1 | |
| SCHEMBL4092971 | 0.81 | KMT2A (0.71) | PYGLPYGMMAPTALDH1A1MEN1 | |
| SCHEMBL7657282 | 0.81 | PYGL (0.55) | PYGLPYGMMAPTALDH1A1MEN1 | |
| SCHEMBL14413319 | 0.80 | LTC4S (0.65) | PYGLPYGMMAPTALDH1A1MEN1 | |
| SCHEMBL2271993 | 0.80 | ALDH1A1 (0.61) | PYGLPYGMMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | KRISTIANSEN MARIT (DK) | 2003-10-02 | — | — | US | claimed |
| US-6590118-B1 | Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) | NOVO NORDISK A/S (DK) | 2003-07-08 | — | — | US | claimed |
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | KRISTIANSEN MARIT (DK) | 2003-10-02 | — | — | US | disclosed |
| US-6593348-B2 | N-substituted(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine compounds; opiod receptors | RESEARCH TRIANGLE INSTITUTE | 2003-07-15 | — | — | US | disclosed |
| US-6590118-B1 | Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) | NOVO NORDISK A/S (DK) | 2003-07-08 | — | — | US | disclosed |
| US-20020193602-A1 | Novel opiate compounds, methods of making and methods of use | RESEARCH TRIANGLE INSTITUTE (US) | 2002-12-19 | — | — | US | disclosed |
| US-20020169324-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RESEARCH TRIANGLE INSTITUTE (US) | 2002-11-14 | — | — | US | disclosed |
| US-20020165396-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RESEARCH TRIANGLE INSTITUTE (US) | 2002-11-07 | — | — | US | disclosed |
| EP-1061919-A4 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RES TRIANGLE INST (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1220832-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001023347-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2001-04-05 | — | — | WO | disclosed |
| EP-1061919-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | Carrol, Frank Ivy (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045925-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RESEARCH TRIANGLE INSTITUTE (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169324-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | OPRK1, OPRM1, OPRL1 | PYGL 674/4885PYGM 1636/4885MAPT 2716/4885 |
| US-20020193602-A1 | Novel opiate compounds, methods of making and methods of use | OPRK1, OPRM1, OPRL1 | PYGL 674/4885PYGM 1636/4885MAPT 2716/4885 |
| US-20020165396-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | OPRK1, OPRM1, OPRL1 | PYGL 674/4885PYGM 1636/4885MAPT 2716/4885 |
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | PYGL, GYS2, PYGM | PYGL 1/4885PYGM 3/4885MAPT 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.